JP2022512796A5 - - Google Patents

Info

Publication number
JP2022512796A5
JP2022512796A5 JP2021522350A JP2021522350A JP2022512796A5 JP 2022512796 A5 JP2022512796 A5 JP 2022512796A5 JP 2021522350 A JP2021522350 A JP 2021522350A JP 2021522350 A JP2021522350 A JP 2021522350A JP 2022512796 A5 JP2022512796 A5 JP 2022512796A5
Authority
JP
Japan
Prior art keywords
ifn
seq
threshold
dhx58
parp9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021522350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059178 external-priority patent/WO2020084591A1/en
Publication of JP2022512796A publication Critical patent/JP2022512796A/ja
Publication of JP2022512796A5 publication Critical patent/JP2022512796A5/ja
Priority to JP2024090820A priority Critical patent/JP2024119889A/ja
Withdrawn legal-status Critical Current

Links

JP2021522350A 2018-10-26 2019-10-25 Ｉ型インターフェロンシグネチャー及び使用方法 Withdrawn JP2022512796A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090820A JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751019P 2018-10-26 2018-10-26
US62/751,019 2018-10-26
PCT/IB2019/059178 WO2020084591A1 (en) 2018-10-26 2019-10-25 Type i interferon signatures and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090820A Division JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Publications (2)

Publication Number Publication Date
JP2022512796A JP2022512796A (ja) 2022-02-07
JP2022512796A5 true JP2022512796A5 (https=) 2022-11-01

Family

ID=70328348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522350A Withdrawn JP2022512796A (ja) 2018-10-26 2019-10-25 Ｉ型インターフェロンシグネチャー及び使用方法
JP2024090820A Pending JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090820A Pending JP2024119889A (ja) 2018-10-26 2024-06-04 Ｉ型インターフェロンシグネチャー及び使用方法

Country Status (10)

Country Link
US (1) US12009079B2 (https=)
EP (1) EP3873523A4 (https=)
JP (2) JP2022512796A (https=)
KR (1) KR20210084528A (https=)
CN (1) CN113692287A (https=)
CA (1) CA3117102A1 (https=)
EA (1) EA202191133A1 (https=)
IL (1) IL282479A (https=)
MA (1) MA54085A (https=)
WO (1) WO2020084591A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114836534A (zh) * 2021-06-08 2022-08-02 中国医学科学院北京协和医院 Samd9l基因突变作为i型干扰素病诊断的标志物及其应用
IL319505A (en) 2022-09-14 2025-05-01 Viatris Asia Pacific Pte Ltd S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon
WO2024100139A1 (en) * 2022-11-09 2024-05-16 Merck Patent Gmbh Use of ifn-i activity as a biomarker for tlr inhibitor treatment
KR20250145681A (ko) * 2023-02-16 2025-10-13 알루미스 인크. 피부과 장애를 치료하는 방법
WO2024173764A1 (en) * 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa
WO2024201091A1 (en) * 2023-03-27 2024-10-03 Institut National de la Santé et de la Recherche Médicale A gene signature for diagnosing stimulator of interferon genes (sting)-associated vasculopathy with onset in infancy (savi)
WO2024216160A1 (en) * 2023-04-14 2024-10-17 Arc Research Institute Methods and compositions for using peli2 as a biomarker
CN117138038A (zh) * 2023-09-21 2023-12-01 北京大学 一种预防、治疗或缓解椎体后纵韧带骨化症的药物
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131066T1 (hr) * 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
EP2712930A3 (en) * 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
CA2686861A1 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US20120035347A1 (en) 2009-04-14 2012-02-09 Schering Corporation Interferon-alfa sensitivity biomarkers
WO2012054284A2 (en) 2010-10-20 2012-04-26 University Of Tennessee Research Foundation Interferon gene signature and methods of use thereof
KR20140048877A (ko) 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법
BR112013030242A2 (pt) 2011-05-25 2016-12-06 Medimmune Llc método de tratamento de um distúrbio autoimune em um sujeito humano
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR102320059B1 (ko) 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
WO2015082716A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10689703B2 (en) * 2015-04-27 2020-06-23 National Jewish Health Methods of identifying and treating subjects having acute respiratory distress syndrome
AU2017279550A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
JP2022527542A (ja) 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法

Similar Documents

Publication Publication Date Title
JP2022512796A5 (https=)
JP7202431B2 (ja) 対象とするヒト標的に特異的に結合するリガンド
US10711059B2 (en) Methods for treating neurodegenerative diseases using anti-PD-L1 antibodies
JP6858182B2 (ja) インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用
RU2014127178A (ru) Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006
US9109034B1 (en) Precision medicine by targeting PD-L1 variants for treatment of cancer
AU2012340624B2 (en) Methods of treatment using an antibody against interferon gamma
US9416180B1 (en) Precision medicine by targeting VEGF-A variants for treatment of diabetic macular edema and branch retinal vein occlusion
US10393739B2 (en) Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US8945560B1 (en) Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) Method of treating atopic dermatitis or asthma using antibody to IL4RA
JP2011511804A (ja) 疾患マーカーおよびその使用
AU2014329535A1 (en) Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
JP2024119889A (ja) Ｉ型インターフェロンシグネチャー及び使用方法
US9017678B1 (en) Method of treating rheumatoid arthritis using antibody to IL6R
JP2023505203A5 (https=)
WO2016071701A1 (en) Treatment of disease using ligand binding to targets of interest
EP3574114A1 (en) Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
US8986691B1 (en) Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) Targeting human NAV1.7 variants for treatment of pain
WO2016023916A1 (en) Treatment of disease using ligand binding to targets of interest
US9150660B1 (en) Precision Medicine by targeting human NAV1.8 variants for treatment of pain
WO2021209902A1 (en) Materials and methods for improved prediction of igg therapeutic protein exposure
TW201527320A (zh) 人類標靶